Nearly 40% up after less than 17 months, we can’t complain, especially with the couple of triple-baggers in the portfolio. The Chinese stocks have disappointed though, and Nano Dimension waited […]
BioLife is a recent addition to the SHU portfolio and one of its highest conviction buys. We were already very positive, but after the Q3CC, we have become more bullish. […]
We clued in to BioLife a couple of months ago, but we found the valuation a little too steep. That has been taken care of. If anything, we see even […]
Terrific acceleration at BioLife and it’s no surprise that the share price has gone parabolic. Revenue growth is accelerating, gross margins are increasing, there is a great deal of operational […]